Conference
Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Authors
Siu LL; Hotte SJ; Laurie SA; Singh S; Winquist E; Chia SKL; Chen EX; Chan KK; Wang T; Taylor I
Volume
29
Pagination
pp. 5561-5561
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.5561
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X